Australia markets closed

SAVA Jan 2024 40.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
17.50-2.95 (-14.43%)
At close: 11:29AM EST
Full screen
Previous close20.45
Expiry date2024-01-19
Day's range17.50 - 19.50
Contract rangeN/A
Open interest433
  • Motley Fool

    Why Cassava Sciences Stock Soared Today

    Ambitious biotech Cassava Sciences (NASDAQ: SAVA) had a fine Friday on the stock market, with its shares closing more than 17% higher. Cassava, which concentrates its efforts on treatments for Alzheimer's disease, said that it had appointed three new members to its board of directors. Of the trio, two are seasoned veterans in the healthcare industry, and the third has notable experience in cybersecurity and emergency-response management.

  • GlobeNewswire

    Cassava Sciences Appoints Three New Members to its Board of Directors

    Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted i

  • Simply Wall St.

    Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?

    With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s...